---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Economic burden and healthcare resource utilization. Topics: Total annual U.S. cost of psoriasis in 2013 U.S. dollars: systematic review of 22 studies; Annual U.S. burden by component: incremental medical costs, quality of life, and productivity, 2013; All-cause costs and resource use in moderate-to-severe psoriasis versus matched controls: OptumHealth claims, 2007 to 2012; Annual all-cause costs in psoriasis versus matched controls: U.S. claims study; 14 further topics. 18 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Total annual U.S. cost of psoriasis in 2013 U.S. dollars: systematic review of 22 studies

> “Among 100 identified articles, 22 studies were included in the systematic review. The direct psoriasis costs ranged from $51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, and medical comorbidities were estimated to contribute $36.4 billion annually in 2013 US dollars.”
> “The annual US cost of psoriasis amounted to approximately $112 billion in 2013.”

Source: [Brezinski et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25565304/)

<a id="topic-2.2.1.8.2-2"></a>

### Annual U.S. burden by component: incremental medical costs, quality of life, and productivity, 2013

> “The prevalence of psoriasis in the US was estimated to be 7.4 million in 2013. Comparatively, psoriasis patients incurred incremental medical costs of $2284, experienced a $2203 reduction in HRQOL, and a $1935 reduction in productivity. The total burden of psoriasis was estimated as $35.2 billion, with $12.2 billion in incremental medical costs (35%), $11.8 billion from reduced HRQOL (34%), and $11.2 billion from productivity losses (32%).”

Source: [Vanderpuye-Orgle et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25882886/)

<a id="topic-2.2.1.8.2-3"></a>

### All-cause costs and resource use in moderate-to-severe psoriasis versus matched controls: OptumHealth claims, 2007 to 2012

> “Adults aged 18-64 years with at least 2 PsO diagnoses (ICD-9-CM code 696.1) were identified in the OptumHealth Reporting and Insights claims database from January 2007 to March 2012. Moderate-to-severe PsO patients were identified as those receiving ≥ 1 systemic therapy or phototherapy during the 12-month study period following the index date (randomly selected date after the first PsO diagnosis). Controls were free of PsO and psoriatic arthritis (PsA) and were matched 1:1 with PsO patients on age, gender, and geographic region.”
> “All-cause health care costs and PsO-related costs (PsO treatment costs and PsO-related medical costs, calculated for moderate-to-severe PsO patients only) were calculated as reimbursed amounts from payers and were adjusted to 2012 U.S. dollars using the medical care component of the Consumer Price Index.”
> “Compared with controls, PsO patients incurred higher annual total health care costs per patient ($22,713 vs. $4,993, adjusted cost difference [ACD] = $18,960; P < 0.001), driven by significantly higher costs in all-cause medications ($14,698 vs. $1,101, ACD = $13,990; P < 0.001) and all-cause medical services ($8,015 vs. $3,892, ACD = $3,895; P = 0.002; Figure 2).”
> “During the 12-month study period, the moderate-to-severe PsO patients incurred an average of $13,731 PsO-related costs, a majority of which were attributed to treatment costs for systemic PsO therapies ($12,958) that included biologics, nonbiologics, and phototherapies (Table 5).”
> “In addition, PsO patients were more likely to incur all-cause medical services, including any inpatient admissions (9.3% vs. 6.4%, aOR = 1.3), ER visits (21.4% vs. 16.4%, aOR = 1.3), and outpatient visits (99.0% vs. 84.5%, aOR = 29.3; all P < 0.001). On average, PsO patients had more inpatient admissions (0.15 vs. 0.09, aIRR = 1.3; P = 0.001), ER visits (0.40 vs. 0.27, aIRR = 1.3; P < 0.001), and outpatient visits (20.46 vs. 8.41, aIRR = 2.4; P < 0.001). PsO patients also spent more hospitalization days (1.03 vs. 0.55, aIRR = 1.9; P < 0.001) than controls.”

Source: [Feldman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397856/)

<a id="topic-2.2.1.8.2-4"></a>

### Annual all-cause costs in psoriasis versus matched controls: U.S. claims study

> “To compare healthcare resource utilization and costs among patients with psoriasis, psoriatic arthritis (PsA), and a control group of patients without psoriasis and PsA in the USA.”
> “Healthcare resource utilization and costs (in 2019 USD) were evaluated descriptively and through mixed models for five years of follow-up.”
> “A total of 142,531 psoriasis and 21,428 PsA patients were matched to the control group (N = 163,959). Annual all-cause healthcare costs per patient were $7,470, $11,062, and $29,742 for the control, psoriasis, and PsA groups, respectively. All-cause healthcare costs increased over time and were significantly greater among PsA vs. psoriasis (p < 0.0001) and the control groups (p < 0.0001).”

Source: [Merola et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33934270/)

<a id="topic-2.2.1.8.2-5"></a>

### All-cause costs by severity, psoriatic arthritis, and biologic use over five years: MarketScan claims, 2009 to 2014

> “Administrative data from Truven Health Analytics MarketScan Research Database were used to select adult patients with psoriasis from January 2009 to January 2014.”
> “Costs are presented per-patient-per-year (PPPY) and by years 1, 2, 3, 4, and 5 of follow-up, expressed in 2014 US dollars.”
> “A total of 108,790 psoriasis patients were selected, with a mean age of 46.0 years (52.7% females). Average follow-up was 962 days. All-cause healthcare costs were $12,523 PPPY. Outpatient pharmacy costs accounted for 38.6% of total costs. All-cause healthcare costs were highest for patients on biologics ($29,832), then for patients with psoriatic arthritis ($23,427) and those with moderate-to-severe disease ($21,481). Overall, all-cause healthcare costs and outpatient pharmacy costs presented an upward trend over a 5-year period.”

Source: [Al Sawah et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28635342/)

<a id="topic-2.2.1.8.2-6"></a>

### Costs and outpatient encounters by severity among biologic-treated patients: linked U.S. claims and electronic health records

> “To describe healthcare resource utilization (HCRU) and costs among biologic-treated psoriasis patients in the US, overall and by disease severity.”
> “IQVIA PharMetrics Plus administrative claims data were linked with Modernizing Medicine Data Services Electronic Health Record data and used to select adult psoriasis patients between April 1, 2010 and December 31, 2014.”
> “This study identified 2,130 biologic-treated psoriasis patients: 282 (13%) had mild, 116 (5%) moderate, and 49 (2%) severe disease; 1,683 (79%) could not be classified.”
> “Relative to mild psoriasis patients, patients with moderate or severe disease had more median all-cause outpatient encounters (28.0 [mild] vs 32.0 [moderate], 36.0 [severe]), more median psoriasis-related outpatient encounters (6.0 [mild] vs 7.5 [moderate], 8.0 [severe]), and a higher proportion of overall claims for medications that were psoriasis-related (28% [mild] vs 37% [moderate], 34% [severe]).”
> “Relative to mild psoriasis patients, patients with moderate or severe disease had higher median all-cause total costs ($37.7k [mild] vs $42.3k [moderate], $49.3k [severe]), higher median psoriasis-related total costs ($32.7k [mild] vs $34.9k [moderate], $40.5k [severe]), higher median all-cause pharmacy costs ($33.9k [mild] vs $36.5k [moderate], $36.4k [severe]), and higher median psoriasis-related pharmacy costs ($32.2k [mild] vs $33.9k [moderate], $35.6k [severe]).”

Source: [Murage et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29718756/)

<a id="topic-2.2.1.8.2-7"></a>

### Six-month direct and indirect costs in moderate-to-severe plaque psoriasis: nine U.S. sites

> “A total of 200 adults seeking MSPP treatment enrolled in 9 US sites.”
> “Most patients (79.5%) were prescribed 1 or more MSPP medications (mean: 1.5); 36.0% and 9.0% received self-administered biologics and systemic therapies, respectively. Mean number of nonprescription treatments was 12.3. Differences by PASI group were observed for overall work and activity impairment (P < .02). Six-month total MSPP direct costs per patient were $11,291; indirect costs were $2101 and differed across PASI groups (P = .0008).”

Source: [Schaefer et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26253364/)

<a id="topic-2.2.1.8.2-8"></a>

### Annual medication costs, biologics versus oral systemic therapies, and visit use by severity: U.S. dermatology electronic health records

> “Data for adults (≥18-years) with a dermatology provider-given diagnosis of psoriasis from 9/2014–9/2015 were obtained from dermatology practices using a widely used US dermatology-specific EHR containing over 500,000 psoriasis patients.”
> “In 28,754 patients, higher disease severity was associated with increased healthcare resource utilization (increased visit frequency and complexity). When compared between treatment groups (n = 10,454), healthcare resource utilization was highest for phototherapy. Annual medication costs were higher for biologics ($21,977) than oral systemics ($3413).”

Source: [Armstrong et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6025830/)

<a id="topic-2.2.1.8.2-9"></a>

### Annual net cost of first-line biologics, 2007 to 2021

> “Trends in the proportion of patients initiating each biologic medication and the average estimated annual treatment costs over time, using commercial estimates of net prices accounting for average manufacturer rebates.”
> “Among 76 781 patients with plaque psoriasis who initiated biologic medications, 50.4% were female and 49.6% male, 71.8% were age 30 to 59 years, and 30% had concurrent inflammatory arthritis.”
> “The average annual treatment cost increased from $21 236 in 2007 to $47 125 in 2021. In 2021, costs ranged from $12 413 (infliximab) to $70 043 (risankizumab). If patients initiated the lowest-cost medication in each class, the average annual treatment cost would have been 44% lower in 2021 ($26 363).”

Source: [Rome et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12004245/)

<a id="topic-2.2.1.8.2-10"></a>

### Costs and resource use by biologic treatment pattern: switchers, discontinuers, and nonswitchers

> “Of the 8,710 patients with psoriasis included in the study, 5,000 (57.4%) were categorized as nonswitchers, 1,001 (11.5%) as switchers, and 2,709 (31.1%) as discontinuers. Emergency department and inpatient visits, respectively, were more common among switchers (adjusted incidence rate ratio [95% CI]: 1.10 [0.93-1.30] and 1.13 [0.84-1.53]) and discontinuers (1.50 [1.34-1.63] and 2.05 [1.70-2.48]) than among nonswitchers. Compared with nonswitchers, switchers had higher adjusted mean total health care costs (mean difference [95% CI]: $10,120 [$8,235-$12,033]), which were driven by increased prescription costs ($8,988 [$7,535-$10,610]) and medical costs ($2,746 [$1,090-$4,677]).”
> “Conversely, the adjusted mean total health care cost for discontinuers was lower than that for nonswitchers (mean difference [95% CI]: -$18,611 [-$20,254, -$17,025]) due to reduced prescription costs (-$20,486 [-$21,319, -$19,636]); however, discontinuers had a higher mean medical cost ($3,729 [$1,970-$5,527]).”

Source: [Feldman et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398133/)

<a id="topic-2.2.1.8.2-11"></a>

### Comorbidity-related medical costs in moderate-to-severe psoriasis versus the general population: U.S. claims, 2006 to 2019

> “Comorbidity-related HCRU (incidence rate ratios [IRRs]) and direct medical cost burden (per patient per month [PPPM] 2020 USD) in patients with moderate to severe PsO in the USA, previously apremilast- and biologic-naive, but currently treated, versus the general population were assessed through a retrospective cohort study using IBM (now Merative) MarketScan Commercial and Medicare Claims data (1 January 2006 to 31 December 2019).”
> “These differences (PsO–general population) in HCRU and costs (IRR visits; PPPM) are associated with specific comorbidities, including mental health (1.08; $372), chronic pulmonary disease (1.07; $135), diabetes (1.10; $159), hyperlipidemia (1.13; $203), hypertension (1.13; $305), liver disease (1.21; $360), and obesity (1.12; $145, all P < 0.01).”

Source: [Wu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9823180/)

<a id="topic-2.2.1.8.2-12"></a>

### Total and work-loss costs by number of psoriasis-related comorbidities: U.S. privately insured patients

> “Adults with psoriasis (≥2 diagnoses, the first designated as the index date) and non-psoriasis controls (no psoriasis diagnoses, randomly generated index date) were identified in a US healthcare claims database of privately-insured patients (data between January 2010 and March 2017 were used).”
> “A total of 9,078 psoriasis (mean age = 44 years, 51% female) and 48,704 non-psoriasis (mean age = 41 years, 50% female) patients were selected.”
> “Psoriasis patients incurred greater total healthcare costs (mean cost differences [MCDs] = $1,590, $5,870, and $18,427, in patients with 0, 1-2, and ≥3 comorbidities, respectively [all p < 0.01]), and work-loss-related costs (MCDs = $335, $655, and $1,695, in patients with 0, 1-2, and ≥3 comorbidities, respectively [all p < 0.01]).”

Source: [Pilon et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30523738/)

<a id="topic-2.2.1.8.2-13"></a>

### Work productivity loss and annual indirect costs by severity: Adelphi survey in the U.S. and five European countries

> “To estimate total WPL and related indirect costs, and identify predictors of WPL associated with psoriasis severity in France, Germany, Spain, the U.K. and Italy (EU5) and the U.S.A.”
> “Data from the 2015 Adelphi Real World Psoriasis Disease Specific Programme, analysed for absenteeism, presenteeism and total WPL, were quantified (0–100%) from participants who completed the Work Productivity and Activity Impairment (WPAI) instrument.”
> “Of the 936 respondents (29·6% U.S.A., 70·4% EU5) who completed the WPAI, 32·6%, 40·7% and 26·6% had mild [body surface area (BSA) 0–2%], moderate (BSA 3–10%) and severe (BSA > 10%) psoriasis, respectively.”
> “Mean percentages of total WPL for respondents with mild, moderate and severe psoriasis were 10·1%, 18·9% and 29·4%, respectively.”
> “Mean annual indirect costs due to WPL per patient were highest in the U.S.A. (9591 U.S. dollars, 95% CI 8407–10 775), reflecting a particularly high contribution from presenteeism (9173 U.S. dollars, 95% CI 8063–10 283).”

Source: [Villacorta et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7497177/)

<a id="topic-2.2.1.8.2-14"></a>

### Work productivity and activity impairment and disability by body surface area category

> “By BSA category, the ‘work hours missed’ domain was 2.3%–5.9%, ‘impairment while working’ was 8.4%–19.0%, ‘work hours affected’ was 9.5%–20.0% and ‘daily activities impaired’ was 13.1%–31.5%.”
> “Increasing proportions of patients were disabled as severity increased according to BSA (range: 7%–14%) and IGA (range: 5%–15%; table 1).”

Source: [Strober et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500315/)

<a id="topic-2.2.1.8.2-15"></a>

### Work productivity and activity impairment score differences by severity

> “WPAI scores increased with severity, indicating greater impairment (moderate vs. mild: 11.77, severe vs. mild 18.73).”

Source: [Korman et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27061102/)

<a id="topic-2.2.1.8.2-16"></a>

### Unemployment and missed work days among survey respondents

> “Of note, 12% of patients were unemployed, and 11% worked part-time. Among unemployed patients, 92% cited psoriasis and/or psoriatic arthritis as the sole reasons for not working. Among working patients, 49% missed work days regularly due to psoriasis. Compared to patients with mild psoriasis, patients with severe psoriasis have 1.8 times greater odds to be unemployed after adjusting for age and gender (Adjusted OR = 1.7, 95% CI 1.4–2.3).”
> “In a typical month, among those who missed work days due to psoriasis or PsA, 62% missed 5 days or less, 6.6% missed 6–10 days, and 31% missed more than 10 days.”

Source: [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)

<a id="topic-2.2.1.8.2-17"></a>

### Annual indirect costs by level of skin clearance: employed participants of the CLEAR trial

> “In the CLEAR study, 452 (67%) were employed at baseline and included in this analysis.”
> “U.S. Department of Labor data were used to calculate annual indirect costs due to work productivity loss.”
> “Associated mean annual indirect costs due to work productivity loss per worker decreased with higher PASI improvements: $10,318 for PASI < 50, $6,042 for PASI 50-74, $2,901 for PASI 75-89, and $2,233 for PASI ≥ 90.”

Source: [Feldman et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398100/)

<a id="topic-2.2.1.8.2-18"></a>

### Inability to work or study and monthly out-of-pocket spending among survey respondents

> “Overall, 29% of patients reported that they could not work or study in the week prior to the survey; of these, 98% responded that psoriasis had a very or extremely large impact on their QoL.”
> “Overall, the highest out-of-pocket costs (mean $240 per month) related to healthcare, prescriptions, doctors’ fees, alternative practitioners, dietitians, and complementary medicine, with nonprescription medicines, creams, and lotions being the next highest cost (mean $147 per month).”

Source: [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
